OncoMatch/Clinical Trials/NCT05908409
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Is NCT05908409 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies IDP-121 for multiple myeloma (mm).
Treatment: IDP-121 — The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: concomitant anti-tumor therapy
Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1.
Cannot have received: allogeneic transplantation
Exception: allowed if >3 months prior and no active GVHD with immunosuppressive treatment
Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment
Lab requirements
Blood counts
Hemoglobin >8.0 g/dl (no transfusion support within 7 days); Platelets >75 x10^9/L (no transfusion support within 7 days; ≥50 x10^9/L if bone marrow infiltration); ANC >0.75 x10^9/L (no G-CSF support within 7 days)
Kidney function
Creatinine clearance >30 mL/min (Cockcroft-Gault)
Liver function
AST <2.5 x ULN (or <5 x ULN with liver metastases); ALT <2.5 x ULN (or <5 x ULN with liver metastases); total bilirubin <2 x ULN
Cardiac function
Left ventricular ejection fraction >50% or above institutional LLN by echocardiogram
Adequate hematological or biochemical parameters as specified below... Left ventricular ejection fraction >50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify